Pierre Breber, David Cush, Sarah Feinberg, David Grissen, Gregg Saretsky and Patricia Watson (the “New Directors”) were each appointed to the Company’s Board of Directors (the “Board”), effective 11:59 p.m. Central Time on November 1, 2024.
Pierre Breber, David Cush, Sarah Feinberg, David Grissen, Gregg Saretsky and Patricia Watson (the “New Directors”) were each appointed to the Company’s Board of Directors (the “Board”), effective 11:59 p.m. Central Time on November 1, 2024.
Pierre Breber, David Cush, Sarah Feinberg, David Grissen, Gregg Saretsky and Patricia Watson (the “New Directors”) were each appointed to the Company’s Board of Directors (the “Board”), effective 11:59 p.m. Central Time on November 1, 2024.
Pierre Breber, David Cush, Sarah Feinberg, David Grissen, Gregg Saretsky and Patricia Watson (the “New Directors”) were each appointed to the Company’s Board of Directors (the “Board”), effective 11:59 p.m. Central Time on November 1, 2024.
Pierre Breber, David Cush, Sarah Feinberg, David Grissen, Gregg Saretsky and Patricia Watson (the “New Directors”) were each appointed to the Company’s Board of Directors (the “Board”), effective 11:59 p.m. Central Time on November 1, 2024.
To fill the vacancy created by Ms. Du’s resignation, the board of directors of the Company (the “Board”) appointed Ms. Fawn Ren to serve as a Class III director of the Board, effective as of November 6, 2024.
On November 6, 2024, Mark Riegel, serving as a Director of the Board of Directors (the “Board”) of Rocky Mountain Chocolate Factory, Inc. (the “Company”), notified the Board of his intention to resign effective November 6, 2024.
Edwina Kelly, notified the Chairman and Chief Executive Officer of Essential Utilities, Inc. (the “Company”) of her resignation, effective as of the date thereof, from her position as a member of the Board of Directors of the Company
On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.
On November 6, 2024, CCC Intelligent Solutions Holdings Inc. (the “Company”) appointed Neil E. de Crescenzo as a Class II Director of the Company and as member of the Audit Committee of the Board of Directors of the Company (the “Audit Committee”), each effective immediately.
Departed
Jane F. Barlow
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Stephen Rubino
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Sam Murphy
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Jane Chung
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Michael W. Sutherlin
Director
RADIUS RECYCLING, INC.
Effective
2024-11-03
Filed
November 6, 2024, 6:59 PM ET
On November 3, 2024, Michael W. Sutherlin notified Radius Recycling, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”) effective as of November 3 rd .
Appointed
Mauro Gregorio
Director
RADIUS RECYCLING, INC.
Effective
2024-11-01
Filed
November 6, 2024, 6:59 PM ET
The Board now consists of seven members, the same number it had immediately prior to the appointment of its most recent independent Board member, Mauro Gregorio, who joined the Board effective November 1, 2024.
On and effective November 6, 2024, the Board of Directors (the “Board”) of SolarEdge Technologies, Inc. (the “Company”) appointed Mr. Guy Gecht to the Board as a Class II director
On November 3, 2024, Mojdeh Poul informed the board of directors (the “Board”) of Stanley Black & Decker, Inc. (the “Company”) of her decision not to stand for re-election as a director of the Company at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”).
On November 5, 2024, the Board of Directors (the “Board”) of Chimera Investment Corporation (the “Company”) elected Cynthia B. Walsh to the Company’s Board as a Class III Director, effective December 1, 2024.
On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.
On October 31, 2024, in connection with the IPO, Matthew Hong, Jennifer Vescio, Josh Gold and Ted Seides (the “ New Directors ” and, collectively with Thomas Bushey, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On October 31, 2024, in connection with the IPO, Matthew Hong, Jennifer Vescio, Josh Gold and Ted Seides (the “ New Directors ” and, collectively with Thomas Bushey, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On October 31, 2024, in connection with the IPO, Matthew Hong, Jennifer Vescio, Josh Gold and Ted Seides (the “ New Directors ” and, collectively with Thomas Bushey, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On October 31, 2024, in connection with the IPO, Matthew Hong, Jennifer Vescio, Josh Gold and Ted Seides (the “ New Directors ” and, collectively with Thomas Bushey, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
be appointed as a Class III director of the Board of Directors
Departed
Jacques N. Gordon
Director
JLL Income Property Trust, Inc.
Effective
2024-11-05
Successor
Lisa L. Kaufman
Filed
November 6, 2024, 6:59 PM ET
On November 5, 2024, Jacques N. Gordon tendered his resignation from his position as a member of the Board of Directors (the "Board") of JLL Income Property Trust, Inc. (the "Company"), effective as of November 5, 2024.
Appointed
Lisa L. Kaufman
Director
JLL Income Property Trust, Inc.
Effective
2024-11-05
Filed
November 6, 2024, 6:59 PM ET
On November 5, 2024, the Board elected Lisa L. Kaufman to the Board to serve as a director and to fill the vacancy created by Mr. Gordon’s resignation, effective as of November 5, 2024.
On November 2, 2024, the board of directors (the “Board”) of the Company, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Jill Hoggard Green to the Board, effective December 1, 2024.
On November 4, 2024, the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”), upon the recommendation of its Nominating and Governance Committee, elected Dame Louise Makin DBE as a director with an initial term expiring on the date of the Company’s 2025 Annual Meeting of Stockholders.
On October 30, 2024, Wetteny Joseph, a member of the Board of Directors (the “Board”) of Ashland Inc. (the “Company”), notified the Company of his decision to not stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).
On November 1, 2024, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Carrie Leigh to fill the vacancy created by the increase in the number of directors.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.